Clinical Trials Logo
  1. Home
  2. Anticoagulants; Increased
  3. NCT03926780

Comparative Study of Oral Anticoagulation in Left Ventricular Thrombi — No-LVT  

Anticoagulants; Increased Clinical Trial

Official title:
Comparative Study of Oral Anticoagulation in Patients With Left Ventricular Thrombi

Clinical Trial Summary

Left ventricular (LV) thrombus is a common problem that is encountered in patients who survived from a large myocardial infarction, and distal systemic embolization is the main issue in these patients due to its major clinical consequences especially cerebrovascular stroke.

Novel oral anticoagulants (NOACs) are now used safely in nonvalvular atrial fibrillation, these agents were shown to be at least as effective as Vitamin K antagonists (VKA) such as warfarin in prevention of systemic embolism, while having an improved safety profile with less bleeding risk. However, the data about their usage for LV thrombi instead of the commonly used VKA are still lacking except for case reports and small case series.

The proposed aim of this randomized observational clinical trial is to assess the efficacy of the conventional anticoagulation in the form of warfarin and NOACs in the form of rivaroxaban in the treatment of LV thrombus.

Clinical Trial Description

The proposed aim of this randomized observational clinical trial is to assess the efficacy of the conventional anticoagulation in the form of warfarin and NOACs in the form of rivaroxaban in the treatment of LV thrombus.

So patients with actual LV thrombus will be divided into 2 groups, one will receive the traditional therapy which is warfarin with follow up of the INR in order to reach the desired level of 2-3 then follow up every two weeks to determine the time in therapeutic range until the end of the study follow up. The other group will receive oral rivaroxaban 20 mg per day with follow up for the persistence or the disappearance of the LV thrombus one month, three months and 6 months later.

As a secondary and safety end point, any major bleeding will be recorded as well as any thrombo-embolic events ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03926780
Study type Interventional
Source The Young Investigator Group of Cardiovascular Research
Contact
Status Completed
Phase Phase 3
Start date December 1, 2018
Completion date May 1, 2020
View Details
See also
  Status Clinical Trial Phase
Completed NCT04719182 - Practice of Adjunctive Treatments in Intensive Care Unit Patients With COVID-19
Not yet recruiting NCT04849312 - Prediction of 30-Day Readmission Using Machine Learning
Active, not recruiting NCT04784351 - Prediction of Expected Length of Hospital Stay Using Machine Learning
Active, not recruiting NCT05045742 - Prediction of Patient Deterioration Using Machine Learning
Recruiting NCT03885180 - Randomized Evaluation of D-dimer Guiding dUration of Oral antiCoagulation thErapy N/A
Completed NCT03203759 - Hospital-Level Care at Home for Acutely Ill Adults N/A
Not yet recruiting NCT04891861 - Restart TICrH Alpha Pilot Protocol, Restarting DOACs After Traumatic Intracranial Hemorrhage Phase 3
Not yet recruiting NCT05705076 - Efficacy of Direct Oral Anticoagulants as a Prophylactic Anticoagulation of Catheter Induced Thrombosis N/A
Recruiting NCT03524222 - Home Hospital for Suddenly Ill Adults N/A
Completed NCT04531280 - Rural Home Hospital: Proof of Concept N/A
Recruiting NCT06341231 - Personalized Anticoagulant Therapy for Pulmonary Thromboembolism
Completed NCT04080570 - Remote Physician Care for Home Hospital Patients N/A
Not yet recruiting NCT03217799 - Noninvasive Measurement of Blood Coagulation N/A